Background We investigated the contribution of subsequent therapy for advanced
hepatocellular carcinoma refractory or intolerant to sorafenib. Further, we investigated the …

Background/Aim: Sorafenib is currently the only medical treatment with proven efficacy
against hepatocellular carcinoma (HCC). HCC cell lines display heterogeneous sensitivity to …

Purpose of study Hepatocellular carcinoma (HCC) is the third leading cause of cancer
death. Although sorafenib has been shown to improve survival of patients with advanced …

Hepatocellular carcinoma (HCC) is one of the most common and challenging malignant
disease. The prognosis is poor in patients with advanced disease. Although sorafenib …

Background Given the well-documented adverse side effects of sorafenib, many sorafenib-
treated patients may need the reduced initial dose of the compound, and an alternative …

BACKGROUND: Sorafenib is currently approved for advanced hepatocellular carcinoma
(HCC) and is presently being studied as an adjuvant treatment for HCC following resection …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths
worldwide. Sorafenib, a molecular-targeted drug, is a multi-target oral anti-neoplastic drug …

Hepatocellular carcinoma (HCC) is a common cause of cancer‐related death. Sorafenib
prolongs survival of patients with advanced disease and is approved for the systemic …

Sorafenib, an orally-available kinase inhibitor, is the only medical treatment with a proven
efficacy against Hepatocellular Carcinoma (HCC). Although the overall clinical efficacy of …

Unlike most solid tumors, the incidence and mortality of hepatocellular carcinoma (HCC)
have increased in the United States and Europe in the past decade. Most patients are …